Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

NCT06679582 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated Early

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Luveltamab tazevibulin

Sponsor

Sutro Biopharma, Inc.

Collaborators

[object Object]
[object Object]